HY-2003

HY-2003 is an investigational drug developed by Sichuan Huiyu Pharmaceutical. It is currently in Phase 1 clinical trials for the treatment of moderate to severe submental fat accumulation (commonly known as "double chin"). The drug is being evaluated for its safety, efficacy, and pharmacokinetic properties when administered via subcutaneous injection into the fat layer beneath the chin. The primary goal of ongoing studies is to assess different doses and dosing frequencies compared to placebo and a positive control[1][2][3]. The precise mechanism of action and molecular target(s) for HY-2003 have not been disclosed in public sources as of April 2025. Development appears focused on aesthetic indications related to localized adiposity under the chin.

Other names

liposome-encapsulated deoxycholic aciddeoxycholic acid liposome injection